The content on this site is intended for healthcare professionals only
Dr Dimopolous presents results at EHA 23 from the iNNOVATE trial of rituximab with or without oral BTK-inhibitor ibrutinib to Waldenströms Macroglobulinemia.
He outlines the study design, with patients randomised 1:1 to receive ibrutinib or placebo orally until disease progression, and the improved progression-free survival of those patients receiving the added therapy.
No unexpected toxicities were reported in the trial, and response rates exceed those of patients receiving rituximab based therapy alone.
For more on this trial, watch presentation of the data at a press session here.
Oncologists' perspectives and practices on minimal residual disease testing in multiple myeloma
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Advancements in paediatric Acute lymphoblastic leukemia management
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
GIST tumours and soft tissue sarcomas
A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM
Importance of MRD in newly developed multiple myeloma
Best practice in HRRm testing in patients with metastatic prostate cancer
